ArticleCureus2025
Cortisol as a Predictor of Nocturnal Hypoglycemia in Insulin-Treated Diabetes: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNocturnal hypoglycemia (NH) is a major clinical concern in insulin-treated diabetes due to blunted autonomic responses and reduced awareness of hypoglycemia during sleep. We investigated the association between NH and early morning fasting cortisol levels in this population.
methodsThis case-control study included 30 insulin-treated adults with type 1 diabetes (n = 22) or advanced type 2 diabetes (n = 8) and depleted endogenous insulin secretion. Glucose profiles were assessed using intermittently scanned continuous glucose monitoring. NH was defined as glucose levels <70 mg/dL between 00:00 and 06:00. Fasting-morning serum cortisol, plasma glucagon, and serum C-peptide levels were also measured. The clinical and biochemical parameters were compared between patients with and without NH.
resultsNH occurred in 15 of 30 patients (50.0%), including three (10.0%) with level 2 hypoglycemia (<54 mg/dL). There were no significant differences between the groups in terms of age, diabetes type, disease duration, HbA1c level, body mass index (BMI), insulin dose, or C-peptide level. However, fasting cortisol levels were significantly lower in patients with NH. Logistic regression analysis showed that lower cortisol levels were independently associated with NH (odds ratio: 0.708; 95% confidence interval: 0.52-0.97; p < 0.05). Receiver operating characteristic curve analysis identified a cortisol threshold of 10.7 μg/dL for predicting NH (area under the curve = 0.79, sensitivity = 0.73, specificity = 0.80).
conclusionsLower early morning cortisol levels may serve as an independent risk factor for NH in patients with insulin-treated diabetes. Cortisol measurements may help identify individuals at risk of asymptomatic NH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.